Verastem (VSTM)
(Delayed Data from NSDQ)
$2.88 USD
+0.05 (1.77%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $2.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
VSTM 2.88 +0.05(1.77%)
Will VSTM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VSTM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VSTM
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
VSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
Other News for VSTM
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
Buy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel Optimism